Galecto Biotech secures €79m in Series C funding to advance idiopathic pulmonary fibrosis treatment

Galecto Biotech secures €79m in Series C funding to advance idiopathic pulmonary fibrosis treatment

Galecto Biotech, a Denmark-based pharmaceutical company specializing in galectin modulators for severe diseases like idiopathic pulmonary fibrosis (IPF) and cancer, has successfully raised €79 million through a Series C financing round. This funding was co-led by Ysios Capital and OrbiMed. New and Existing Investors Support Galecto Biotech’s Growth The Series C round saw participation from […]

Syneron Candela acquires Danish medical device company Ellipse

Syneron Candela acquires Danish medical device company Ellipse

Medical industry news : Syneron Candela, a US-based aesthetic device company, has announced the acquisition of Danish medical device company Ellipse for an undisclosed price. The financial terms of Syneron Candela acquisition of Ellipse have not been disclosed. Ellipse is engaged in manufacturing Intense Pulsed Light (IPL) and laser-based platforms for a range of medical […]

LEO Pharma secures global rights to JW1601 in $402m deal with JW Pharmaceutical

LEO Pharma secures global rights to JW1601 in $402m deal with JW Pharmaceutical

LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant deal valued at approximately KRW 450 billion ($402 million). This licensing agreement, however, excludes South Korea, where JWP will retain exclusive rights. Under the terms of the agreement, LEO Pharma […]

Novo Nordisk acquires Ziylo in $800m deal to advance diabetes treatment

Novo Nordisk acquires Ziylo in $800m deal to advance diabetes treatment

Novo Nordisk, a leading Danish pharmaceutical company, has completed a significant acquisition of Ziylo, a biotechnology spin-out from the University of Bristol, for a deal potentially worth over $800 million. This acquisition grants Novo Nordisk full rights to Ziylo’s innovative glucose binding molecules, crucial for the development of glucose responsive insulins. Strategic Importance of the […]

Danish Crown acquires Danish pepperoni topping producer DK-Foods

Danish Crown acquires Danish pepperoni topping producer DK-Foods

Food acquisition news : Meat processing company Danish Crown has acquired DK-Foods, a Danish pepperoni topping producer which supplies the popular pizza topping to pizza manufacturers across Europe. The financial terms of Danish Crown acquisition of DK-Foods have not been disclosed. Through the acquisition, the Danish meat processing company aims to become a market leader […]

Lundbeck to acquire Prexton Therapeutics in $1.1bn deal to expand Parkinson’s Disease treatment portfolio

Lundbeck to acquire Prexton Therapeutics in $1.1bn deal to expand Parkinson’s Disease treatment portfolio

Lundbeck, a leading Danish pharmaceutical company, has announced its acquisition of Prexton Therapeutics, a Swiss firm specializing in the development of drugs for Parkinson’s disease, in a deal valued at approximately $1.1 billion. This strategic acquisition is set to enhance Lundbeck’s capabilities in neurology, particularly in the treatment of Parkinson’s disease. Financial Structure of the […]

Orkla acquires Danish bakery company Struer Brod

Orkla acquires Danish bakery company Struer Brod

Food acquisition news : Norwegian conglomerate Orkla has purchased Danish bakery company Struer Brod for an undisclosed price through its wholly-owned subsidiary Orkla Foods Sverige. Orkla acquisition of Struer Brod is aimed at bolstering its production capacity in the breakfast segment. Struer Brod manufactures breakfast cereals and breadcrumbs with Orkla being its key customer. The […]

FDA approves Novo Nordisk’s Victoza for cardiovascular disease treatment in type 2 diabetes patients

FDA approves Novo Nordisk’s Victoza for cardiovascular disease treatment in type 2 diabetes patients

Novo Nordisk’s diabetes medication, Victoza (liraglutide), has gained U.S. Food and Drug Administration (FDA) approval for an expanded use, marking a significant step forward in the treatment of cardiovascular diseases among type 2 diabetes patients. This latest approval allows Victoza to be used to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular […]

1 5 6 7